Biotech | 16 March 2024
Evonik Vland Biotech JV commences operations
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
It is the first autotaxin inhibitor to be investigated in cancer patients
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Multi-ethnic innovation helps all complexions appear clearer and more uniform
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Apollo continues to invest in genomics technology and research for better patient care
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Subscribe To Our Newsletter & Stay Updated
